1. Global Corporate Venturing:
Healthcare Innovation

2. Penetration of CVC by Industry
Source: BCG, October 2012, analysing Global Corporate Venturing’s data

4. New health funds and commitments
GSK’s $50m bioelectronic fund and LP commitment to Kurma Biofund II
Stanford-StartX
Cipla incubator
BI joins Rockspring
Amgen and Novartis partner with Atlas
Bayer and Roche to QB3
MS Ventures doubles to €100m
Quintiles’ NovaQuest
Source: Sample selected Venturing.com in 2013

5. Q2 Fundraising and Trends
Parent
Corporate Venturing Unit/Fund
Size
Parent's Region
Sector
Tata
Tata Opportunities Fund
$600m
Asia
Industrial
Unilever
Unllever Ventures
$450m
Europe
Consumer
SAP
Hana Fund
$250m* IT
Shell
Shell Technology Ventures
$100ms*
Energy
Merck
MS Ventures
€100m*
Health
Grupo RBS
e.Bricks Digital
$100m
RoW
Infosys
Fund
Giant Interactive Group
Pleb Dream Fund
RMB1bn ($161m) 
Media
Intel
Perceptual fund US
Quintiles
NovaQuest
$80m
Source: Global Corporate Venturing
* expansion of existing fund

7. Healthcare CVC’s narcissism
Source: BCG, October 2012, analysing Global Corporate Venturing’s 1,300 deals

8. Source: Global Corporate Venturing

9. Deal Activity
Source: Global Corporate Venturing

10. Q activity
Source: Global Corporate Venturing

11. Q2 Deal Activity 246 investments worth $5bn
40 exits – IPOs picking up by number
M&A from portfolio companies up by a third
Series A leads by number of deals
IT most active, healthcare rebounds,
Asia and Europe increasing but US leads

12. Contact: James Mawson, founder and editor-in-chief
“A global, multimedia publishing group dedicated to serving the intermediaries directing funding to entrepreneurs in the innovation economy.”
Contact: James Mawson, founder and editor-in-chief
(US main) or +44 (0) (UK)